Dr. Jaime Chu is an Assistant Professor of Pediatrics in the Division of Pediatric Hepatology at the Kravis Children’s Hospital and Mount Sinai’s Recanati/Miller Transplantation Institute. She received her B.A. magna cum laude from Harvard University and her M.D. from New York University School of Medicine. She completed her General Pediatrics residency training at Children’s Memorial Hospital at Northwestern University in Chicago, IL and her fellowship in Pediatric Gastroenterology, Hepatology, and Nutrition both at Children’s Memorial Hospital and at the Mount Sinai School of Medicine.
Certifications
Pediatric Gastroenterology
Clinical Focus
- Acute and Chronic Liver Failure
- Autoimmune Hepatitis
- Biliary atresia
- Cholestatic disorders
- Congenital hepatic fibrosis
- Liver Transplant
- Metabolic liver disease
- Nonalcoholic fatty liver disease
- Portal Hypertension
Education
MD, New York University School of Medicine
BA, Harvard University
MD, New York University School of Medicine
Residency, Pediatrics, Children's Memorial Hospital
Fellowship, Pediatric Gastroenterology, Children's Memorial Hospital
Fellowship, Pediatric Gastroenterology, Mount Sinai School of Medicine
Glycosylation and Cancer Metabolism
Dr. Chu is both a clinician and an NIH-funded physician-scientist, leading a research team investigating the intersection of glycosylation and cancer metabolism with special focus on congenital disorders of glycosylation (CDG).
CDG are rare—only an estimated 1,000 patients identified worldwide—and underdiagnosed genetic disorders. Children born with CDG have discrete defects in the processes that are essential for protein secretion and function, and present with debilitating, multisystemic disease. These patients develop signs of common liver and gastrointestinal diseases, making the study of CDG particularly relevant to the broader field of liver disease, as steatosis, fibrosis, and cirrhosis have all been associated with defects in protein glycosylation.
Dr. Chu has been the recipient of several National Institutes of Health (NIH) grants (T32, K12), and recently, a Mentored Clinical Scientist Development Award (K08) to further examine the role of p53 in CDG. Previously, Dr. Chu, with Kirsten Sadler Edepli, PhD, Associate Professor of Medicine (Liver Diseases), and Developmental and Regenerative Biology, has participated in a national consortium funded by an NIH American Recovery and Reinvestment Act grant, and were the first to establish zebrafish as a model to study CDG.
Dr. Chu is also a member of The Mindich Child Health and Development Institute, the translational research enterprise that works closely with the Department of Pediatrics, to advance knowledge and therapies for pediatric diseases.
Bambino K, Zhang C, Austin C, Amarasiriwardena C, Arora M, Chu J, Sadler KC. Inorganic arsenic causes fatty liver and interacts with ethanol to cause alcoholic liver disease in zebrafish. Disease models & mechanisms 2017 Dec;.
DeRossi C, Shtraizent N, Nayar S, Sachidanandam R, Katz LS, Prince A, Koh AP, Vincek A, Hadas Y, Hoshida Y, Scott DK, Eliyahu E, Freeze HH, Sadler KC, Chu J. MPI depletion enhances O-GlcNAcylation of p53 and suppresses the Warburg effect. eLife 2017 Jun; 6.
Lai J, Chu J, Arnon R. Pediatric liver transplantation for fulminant hepatic failure secondary to intentional iron overdose. Pediatric transplantation 2017 Jun;.
Jossen J, Annunziato R, Kim HS, Chu J, Arnon R. Liver Transplantation for Children With Primary Sclerosing Cholangitis and Autoimmune Hepatitis: UNOS Database Analysis. Journal of pediatric gastroenterology and nutrition 2017 Apr; 64(4).
Ramaswami A, Rosen DJ, Chu J, Wistinghausen B, Arnon R. Fulminant Liver Failure in a Child With β-Thalassemia on Deferasirox: A Case Report. Journal of pediatric hematology/oncology 2017 Apr; 39(3).
Shakhin V, Iyer K, Chu J, Ramaswami A, Lester N, Arnon R. Roux-en-Y intussusception after pediatric liver transplant - A case report. Pediatric transplantation 2016 Jun;.
Bambino K, Chu J. Zebrafish in Toxicology and Environmental Health. Current topics in developmental biology 2017; 124.
DeRossi C, Vacaru A, Rafiq R, Cinaroglu A, Imrie D, Nayar S, Baryshnikova A, Milev MP, Stanga D, Kadakia D, Gao N, Chu J, Freeze HH, Lehrman MA, Sacher M, Sadler KC. trappc11 is required for protein glycosylation in zebrafish and humans. Molecular biology of the cell 2016 Feb;.
Arnon R, Annunziato RA, D'Amelio G, Chu J, Shneider BL. Liver Transplantation For Biliary Atresia: Is There A Difference In Outcome For Infants?. Journal of pediatric gastroenterology and nutrition 2015 Sep;.
Rosen D, Chu J, Morotti R, Levanon D, Rose S, Lee S, Arnon R. Hepatitis C Virus-Autoimmune Hepatitis Overlap Syndrome in an Adolescent. Journal of pediatric gastroenterology and nutrition 2015 Aug; 61(2).
Rosen D, Thung S, Sheflin-Findling S, Lai J, Rosen A, Arnon R, Chu J. IgG4-Sclerosing Cholangitis in a Pediatric Patient. Seminars in liver disease 2015 Feb; 35(1).
Sheflin-Findling S, Annunziato RA, Chu J, Arvelakis A, Mahon D, Arnon R. Liver transplantation for neonatal hemochromatosis: Analysis of the UNOS database. Pediatric transplantation 2015 Jan;.
Jossen J, Chu J, Hotchkiss H, Wistinghausen B, Iyer K, Magid M, Kamath A, Roayaie S, Arnon R. Epstein-Barr virus-associated smooth muscle tumors in children following solid organ transplantation: A review. Pediatric transplantation 2015 Jan;.
Rosen D, Chu J, Patel R, Moon J, Iyer K, Arnon R. Balloon-occluded retrograde transvenous obliteration for recurrent fundal gastric variceal bleeding in an adolescent. Pediatric transplantation 2014 Sep; 18(6).
Rosen D, Chu J, Morotti R, Levanon D, Rose S, Lee S, Arnon R. Hepatitis C Virus-Autoimmune Hepatitis Overlap Syndrome in an Adolescent: Case Report and Review of the Literature. Journal of pediatric gastroenterology and nutrition 2013 Dec;.
Arnon R, Annunziato RA, Willis A, Parbhakar M, Chu J, Kerkar N, Shneider BL. Liver transplantation for children with biliary atresia in the pediatric end-stage liver disease era: the role of insurance status. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2013 May; 19(5).
Chu J, Mir A, Gao N, Rosa S, Monson C, Sharma V, Steet R, Freeze HH, Lehrman MA, Sadler KC. A zebrafish model of congenital disorders of glycosylation with phosphomannose isomerase deficiency reveals an early opportunity for corrective mannose supplementation. Disease models & mechanisms 2013 Jan; 6(1).
Kerkar N, D'Urso C, Van Nostrand K, Kochin I, Gault A, Suchy F, Miloh T, Arnon R, Chu J, Annunziato R, Sadler KC. Psychosocial outcomes for children with nonalcoholic fatty liver disease over time and compared with obese controls. Journal of pediatric gastroenterology and nutrition 2013 Jan; 56(1).
Sheflin-Findling S, Arnon R, Lee S, Chu J, Henderling F, Kerkar N, Iyer K. Partial internal biliary diversion for Alagille syndrome: case report and review of the literature. Journal of pediatric surgery 2012 Jul; 47(7).
Chu J, Loughlin EA, Gaur NA, SenBanerjee S, Jacob V, Monson C, Kent B, Oranu A, Ding Y, Ukomadu C, Sadler KC. UHRF1 phosphorylation by cyclin A2/cyclin-dependent kinase 2 is required for zebrafish embryogenesis. Molecular biology of the cell 2012 Jan; 23(1).
Chu J, Kerkar N, Miloh TA, Rodriguez-Laiz G, Lewis B, Stangl A, Newton KP, Iyer K, Arnon R, Sadler KC. Roux-en-Y loop varices in children with portal hypertension after liver transplantation: an unusual cause of . Pediatric transplantation 2011 Dec; 15(8).
Chu J, Sadler KC. New school in liver development: lessons from zebrafish. Hepatology 2009 Nov; 50(5).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Chu did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.